ISRCTN58648476 https://doi.org/10.1186/ISRCTN58648476

# A randomised double-blind controlled trial of BCNU as second-line therapy in metastatic oesophago-gastric, colorectal and pancreatic cancer

| | | |
|---|---|---|
| **Submission date**<br>19/08/2002 | **Recruitment status**<br>No longer recruiting | [_] Prospectively registered<br>[_] Protocol<br>[_] Statistical analysis plan<br>[_] Results<br>[_] Individual participant data<br>[_] Record updated in last year |
| **Registration date**<br>19/08/2002 | **Overall study status**<br>Completed | |
| **Last Edited**<br>15/12/2015 | **Condition category**<br>Cancer | |

**Plain English summary of protocol**
Not provided at time of registration

## Contact information

**Type(s)**
Scientific

**Contact name**
Dr - -

**Contact details**
UKCCCR Register Co-ordinator
MRC Clinical Trials Unit
222 Euston Road
London
United Kingdom
NW1 2DA

## Additional identifiers

**Protocol serial number**
RMH E/C 1105

## Study information

**Scientific Title**

A randomised double-blind controlled trial of BCNU as second-line therapy in metastatic oesophago-gastric, colorectal and pancreatic cancer

### Study objectives
Not provided at time of registration

### Ethics approval required
Old ethics approval format

### Ethics approval(s)
Not provided at time of registration

### Primary study design
Interventional

### Study design
Randomised controlled trial

### Study type(s)
Treatment

### Health condition(s) or problem(s) studied
Colon, oesophagus, pancreas, rectum, stomach cancers

### Interventions
1. Arm 1: BCNU 200 mg in 500 ml 5% dextrose
2. Arm 2: 5% dextrose alone

### Intervention Type
Drug

### Phase
Not Applicable

### Drug/device/biological/vaccine name(s)
BCNU

### Primary outcome(s)
Not provided at time of registration

### Key secondary outcome(s)
Not provided at time of registration

### Completion date
31/03/2001

## Eligibility

### Key inclusion criteria

Any patient who has progressed on or has a short disease free interval with folinic acid modulated 5-Fluorouracil (5FU) protracted infusional 5FU regimens

### Participant type(s)
Patient

### Healthy volunteers allowed
No

### Age group
Not Specified

### Sex
Not Specified

### Key exclusion criteria
Not provided at time of registration

### Date of first enrolment
01/01/1995

### Date of final enrolment
31/03/2001

## Locations

### Countries of recruitment
United Kingdom

England

### Study participating centre
**MRC Clinical Trials Unit**
London
United Kingdom
NW1 2DA

## Sponsor information

### Organisation
The Royal Marsden NHS Foundation Trust (UK)

### ROR
https://ror.org/0008wzh48

# Funder(s)

**Funder type**
Hospital/treatment centre

**Funder Name**
Royal Marsden Hospital (UK)

# Results and Publications

**Individual participant data (IPD) sharing plan**

**IPD sharing plan summary**
Not provided at time of registration